

FILE 'REGISTRY' ENTERED AT 10:58:32 ON 13 APR 2004

L1 E TOPIRAMATE/CN
 1 S E3
 E ERYTHROPOITIN
 E ERYTHROPOITIN/CN
 E ERYTHROPOIETIN/CN
L2 1 S E3

=> d l1 l2

L2 IS NOT VALID HERE

For an explanation, enter "HELP DISPLAY".

=> d

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 11096-26-7 REGISTRY
CN **Erythropoietin (9CI)** (CA INDEX NAME)
OTHER NAMES:
CN Ep
CN EPO
CN Epoetin
CN Epogis S
CN Hempoietine
MF Unspecified
CI COM, MAN
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BIOBUSINESS, BIOSIS, BIOTECHNO,
 CA, CABA, CANCERLIT, CAPLUS, CBNB, CEN, CHEMCATS, CHEMLIST, CIN, CSCHM,
 DDFU, DIOGENES, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IMSPATENTS,
 IMSRESEARCH, IPA, MEDLINE, MRCK*, NIOSHTIC, PHAR, PROMT, RTECS*,
 TOXCENTER, USPAT2, USPATFULL, VETU
 (*File contains numerically searchable property data)
Other Sources: EINECS**
 (**Enter CHEMLIST File for up-to-date regulatory information)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

8321 REFERENCES IN FILE CA (1907 TO DATE)

203 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA


8344 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2004 ACS on STN
RN 97240-79-4 REGISTRY
CN β-D-Fructopyranose, 2,3:4,5-bis-O-(1-methylethylidene)-, sulfamate
 (9CI) (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 5H-Bis[1,3]dioxolo[4,5-b:4',5'-d]pyran, β-D-fructopyranose deriv.
OTHER NAMES:
CN 2,3:4,5-Bis-O-(1-methylethylidene) β-D-fructopyranose sulfamate
CN McN 4853
CN RWJ 17021
CN Topamax
CN **Topiramate**
CN Topomax
FS STEREOSEARCH
MF C12 H21 N O8 S
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN*,
 BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB,
 CEN, CHEMCATS, CIN, CSCHM, DDFU, DIOGENES, DRUGU, EMBASE, IMSDRUGNEWS,

IMSPATENTS, IMSRESEARCH, IPA, MEDLINE, MRCK*, PHAR, PROMT, PS, RTECS*,
SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)
Other Sources: WHO

Absolute stereochemistry. Rotation (-).



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

482 REFERENCES IN FILE CA (1907 TO DATE)
11 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
486 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
13.66	13.87

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 11:00:29 ON 13 APR 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Apr 2004 VOL 140 ISS 16

FILE LAST UPDATED: 12 Apr 2004 (20040412/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> d his

(FILE 'HOME' ENTERED AT 10:58:16 ON 13 APR 2004)

10/035753

FILE 'REGISTRY' ENTERED AT 10:58:32 ON 13 APR 2004

L1 E TOPIRAMATE/CN
1 S E3
E ERYTHROPOITIN
E ERYTHROPOITIN/CN
E ERYTHROPOIETIN/CN
L2 1 S E3

FILE 'CAPLUS' ENTERED AT 11:00:29 ON 13 APR 2004

=> s l1 and l2

485 L1

8345 L2

L3 3 L1 AND L2

=> d fbib abs 1-3

L3 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2003:971836 CAPLUS
DN 140:23256
TI Combination therapy for treatment of amyotrophic lateral sclerosis (ALS)
with cyclooxygenase-2 (COX 2) inhibitor(s) and a second drug
IN Isakson, Peter C.
PA Pharmacia Corporation, USA
SO PCT Int. Appl., 358 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003101380	A2	20031211	WO 2003-US14547	20030528
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

US 2002-384104PP 20020531

US 2003-444071 A 20030523

US 2004063751 A1 20040401 US 2003-444071 20030523

US 2002-384104PP 20020531

OS MARPAT 140:23256

AB A method of treating, preventing, or inhibiting ALS, in a subject in need of such treatment, inhibition or prevention. The method comprises administering to a subject one or more cyclooxygenase-2 selective inhibitor(s) or isomer(s) or pharmaceutically acceptable salt(s), ester(s), or prodrug(s) thereof, in combination with one or more second drugs, wherein the amount of the cyclooxygenase-2 selective inhibitor(s) or isomer(s) or pharmaceutically acceptable salt(s), ester(s), or prodrug(s) thereof in combination with the amount of second drug(s) constitutes an ALS treatment, inhibition or prevention effective amount

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:637475 CAPLUS
DN 137:163821

TI Treatment of neurological dysfunction comprising fructopyranose sulfamates and erythropoietin
 IN Plata, Salaman Carlos; Smith-Swintosky, Virginia
 PA Ortho-Mcneil Pharmaceutical, Inc., USA
 SO PCT Int. Appl., 39 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002064085	A2	20020822	WO 2002-US3096	20020124
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 2002169109	A1	20021114	US 2001-266194PP	20010202
				US 2002-56828	20020124
				US 2001-266194PP	20010202
	NO 2003003440	A	20030929	NO 2003-3440	20030801
				US 2001-266194PP	20010202
				WO 2002-US3096 W	20020124

OS MARPAT 137:163821
 AB Co-therapy for the treatment of neurol. dysfunctions comprises administration of one or more fructopyranose sulfamates and erythropoietin. Topiramate and recombinant human EPO showed synergistic effect on neurite outgrowth of cortical neurons.

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:300514 CAPLUS
 DN 134:331617
 TI Oil-in-water emulsion compositions for polyfunctional active ingredients
 IN Chen, Feng-jing; Patel, Mahesh V.
 PA Lipocine, Inc., USA
 SO PCT Int. Appl., 82 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001028555	A1	20010426	WO 2000-US28835	20001018
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

US 1999-420159 A 19991018
 US 2002107265 A1 20020808 US 1999-420159 19991018

AB Pharmaceutical oil-in-water emulsions for delivery of polyfunctional active ingredients with improved loading capacity, enhanced stability, and reduced irritation and local toxicity are described. Emulsions include an

aqueous phase, an oil phase comprising a structured triglyceride, and an emulsifier. The structured triglyceride of the oil phase is substantially free of triglycerides having three medium chain (C6-C12) fatty acid moieties, or a combination of a long chain triglyceride and a polarity-enhancing polarity modifier. The present invention also provides methods of treating an animal with a polyfunctional active ingredient, using dosage forms of the pharmaceutical emulsions. For example, an emulsion was prepared, with cyclosporin A as the polyfunctional active ingredient dissolved in an oil phase including a structured triglyceride (Captex 810D) and a long chain triglyceride (safflower oil). The composition contained (by weight) cyclosporin A 1.0, Captex 810D 5.0, safflower oil 5.0, BHT 0.02, egg phospholipid 2.4, dimyristoylphosphatidyl glycerol 0.2, glycerol 2.25, EDTA 0.01, and water up to 100%, resp.

RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT